Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Fluorouracil stops cells from making DNA and it may kill cancer cells. Both oxaliplatin and fluorouracil are approved by the Food and Drug Administration to treat patients with colorectal cancer, however administration of these drugs

Trial Details

NCT ID

NCT06269978

Phase

PHASE1

Sponsor

Arjun Mittra

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

Biopsy
Biospecimen Collection
Computed Tomography
Diagnostic Laparoscopy
Fluorouracil
Magnetic Resonance Imaging

Locations (sample)

Columbus, Ohio, United States|39.96118,-82.99879
Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

Age \>= 18 years
Biopsy proven colorectal cancer with peritoneal metastasis. Patients with extraperitoneal metastases will not be eligible. Patients with involvemen…
Primary colorectal cancer may either be left in place or have been resected prior to study enrollment
Patients are allowed to have received prior colorectal cancer-directed systemic therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →